NanoViricides, Inc. (NYSE American: NNVC) has released its quarterly report for the period ended March 31, 2026, detailing continued advancement of its broad-spectrum antiviral candidate NV-387 toward Phase II clinical development for MPox in the Democratic Republic of Congo, where regulatory approval for the trial has already been obtained. The company also outlined progress in its orphan-first regulatory strategy, including FDA orphan drug designation for measles granted subsequent to the quarter and additional applications targeting MPox and smallpox.
The news underscores the company's commitment to addressing multiple viral disease targets with a single drug candidate. NV-387 is designed to treat respiratory syncytial virus (RSV), COVID-19, Long COVID, influenza, MPox, smallpox, and measles, among others. This broad-spectrum approach could have significant implications for global health, offering a potential therapeutic option for both emerging and established viral threats.
NanoViricides' orphan drug designations are a key part of its regulatory strategy. Orphan drug status provides incentives such as tax credits and market exclusivity, which can accelerate development and reduce costs. The designation for measles, coupled with pending applications for MPox and smallpox, positions the company to address diseases that disproportionately affect underserved populations and regions with limited healthcare infrastructure.
The Phase II trial for MPox in the DRC is particularly noteworthy given the ongoing outbreak of the virus in Africa. By securing regulatory approval in the DRC, NanoViricides aims to evaluate NV-387's efficacy in a real-world setting where the disease is endemic. Success could lead to a critical treatment option for a virus that has caused significant morbidity and mortality.
The company's technology platform, based on TheraCour nanomedicine, enables the creation of nanoviricide drug candidates that target viruses directly. NV-387 is the lead candidate, and its ability to encapsulate or function independently offers flexibility in treatment approaches. For instance, NV-CoV-2 is the nanoviricide candidate for COVID-19 without remdesivir encapsulation, while NV-CoV-2-R encapsulates remdesivir within its polymeric micelles. The company believes that since remdesivir is already FDA approved, the encapsulated version could be an approvable drug if safety is comparable.
NanoViricides' pipeline also includes candidates for herpes, influenza, HIV, hepatitis C, rabies, dengue, and Ebola, among others. However, the company acknowledges the lengthy and capital-intensive nature of drug development. As with any pharmaceutical candidate, there is no assurance of clinical success or eventual approval.
For investors, the quarterly report provides a snapshot of progress and potential. The company's newsroom at https://ibn.fm/NNVC offers updates and additional information. The full press release is available at https://ibn.fm/osO0q.
